NasdaqCM - Delayed Quote USD

NeuroSense Therapeutics Ltd. (NRSNW)

0.2600

+0.0330

+(14.54%)

At close: April 21 at 4:00:00 PM EDT

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today issued a shareholder letter from Chief Executive Officer Alon Ben-Noon. The letter provides an update on the company's ongoing partnership discussions, regulatory and commercial pathway for PrimeC in ALS, clinical progress, and financial outlook. The full text of the letter is included below.

PR Newswire 10 hours ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company's investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS), on microRNA (miRNA) modulation.

PR Newswire 15 days ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December 31, 2024 and provides a business update.

PR Newswire 17 days ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced that two members of its Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting. The presentations and conference will be taking place in San Diego, CA on April 8, 2025.

PR Newswire 20 days ago

NRSN
+2.52%
NRSNW
+14.54%
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

NEW YORK, March 20, 2025--Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS).

Business Wire last month

NRSN
+2.52%
NRSNW
+14.54%
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NEW YORK, March 17, 2025--PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation, NeuroSense Therapeutics (NASDAQ: NRSN) stands at the forefront of a potential revolution in ALS treatment, developing a groundbreaking combination therapy that could fundamentally transform the approach to one of the most devastating neurological disorders. With clinical data showing a remarkable 36% reduction in

Business Wire last month

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's stockholders' equity requirement ("Equity Requirement") set forth in Nasdaq Listing Rule 5550(b)(1). The Company's Ordinary Shares will continue to be listed and trad

PR Newswire 3 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced today that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis (ALS) in certain key territories. NeuroSense would retain full rights to PrimeC in other key terr

PR Newswire 3 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and third quarter financial results.

PR Newswire 4 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) for PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). The purpose of the meeting was to discuss the design of a proposed Phase 3 clinical study and the plan for submission of an eventual 505(b)(2) marketing applicati

PR Newswire 4 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce today statistically significant positive results from the 18-month data analysis of the PARADIGM study, evaluating the efficacy of PrimeC in the treatment of Amyotrophic Lateral Sclerosis (ALS). These results highlight a significant improvement in ALS Functional Rating Scale-Revised (ALSFRS-R) scores and

PR Newswire 4 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with a single investor and with NeuroSense's Chief Executive Officer, Mr. Alon Ben-Noon, to purchase an aggregate of $5,000,000 of ordinary shares (or ordinary share equivalents) and warrants in a private placement, subject to certain closing conditions.

PR Newswire 4 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce its participation in the 2024 International Symposium on ALS/MND, to be held December 6-8, 2024, in Montreal, Canada.

PR Newswire 4 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it is scheduled for a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of its upcoming Phase 3 clinical trial for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS).

PR Newswire 5 months ago

NRSN
+2.52%
NRSNW
+14.54%
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Monday said it is scheduled for an FDA Type C meeting to discuss the design of its upcoming Phase 3 clinical trial for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS). ALS is a fatal type of motor neuron disease. It causes progressive degeneration of nerve cells in the spinal cord and brain. The FDA Type C meeting, scheduled for November 6, will focus on finalizing the design of the Phase 3 trial, a pivotal step toward securing

Benzinga 5 months ago

NRSNW
+14.54%
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced transformative findings from its PARADIGM clinical trial of PrimeC. These results illuminate a new frontier in the treatment of ALS (Amyotrophic Lateral Sclerosis), a disease long considered untreatable at its core. The trial demonstrating the significant impact of PrimeC on the regulation of microRNAs (miRNAs),

PR Newswire 5 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, provided a further update on its plans to file for early commercialization approval for PrimeC under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This submission is based on promising results from the Company's Phase 2b ALS PARADIGM clinical trial, supported by additional clinical and preclinical data.

PR Newswire 6 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ('NeuroSense'), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has initiated the regulatory process to seek early commercialization approval for PrimeC under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This submission is based on the promising results from the company's Phase 2b ALS PARADIGM clinical trial, alongside supporting clinical and precl

PR Newswire 6 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the acceptance of two abstracts focusing on the company's lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS). These abstracts will be presented at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis (NEALS) Consortium Meeting, taking place October 21 to October 24 in Cle

PR Newswire 6 months ago

NRSN
+2.52%
NRSNW
+14.54%
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the issuance of a pivotal patent by the United States Patent and Trademark Office (USPTO). The newly granted patent, entitled "Compositions comprising Ciprofloxacin and Celecoxib" (US Patent No. US 12,097,185), relates to the novel formulation of PrimeC, NeuroSense's leading drug candidate for the treatment of A

PR Newswire 6 months ago

NRSN
+2.52%
NRSNW
+14.54%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NeuroSense Therapeutics Ltd. (NRSNW)

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's